Core Viewpoint - Neogen Corporation is facing a securities class action lawsuit for failing to disclose material information during the class period from January 5, 2023, to June 3, 2025, which has led to significant stock price declines [1][3]. Summary by Sections Lawsuit Details - The lawsuit is pending in the United States District Court for the Western District of Michigan, with a deadline for lead plaintiff applications set for September 16, 2025 [1]. - The case is titled Operating Eng'rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802 [5]. Financial Performance - On April 9, 2025, Neogen reported a quarterly revenue decrease of 3.4% to $221 million, attributed to integration issues, and subsequently cut its FY25 guidance [4]. - Capital expenditures were projected to be $100 million due to lowered adjusted EBITDA and integration-related expenses [4]. - Following the revenue announcement, Neogen's stock price dropped 28% to close at $5.02 per share on a volume of 47 million shares [4]. - On June 4, 2025, the company indicated that its EBITDA margin would likely be in the high-teens, a significant decline from the previous quarter's margin of 22%, resulting in an additional 17% drop in stock price to $4.96 per share [4]. Investor Support - ClaimsFiler provides a free service for investors to recover funds from securities class action settlements, offering resources for timely claims submission and legal evaluations [6].

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants failed to disclose to investors that: (i) the Compan ...

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down $7.89 (-36%) - after the company reported the death of a third patient who was being treated with one of its experimental gene therapy drugs. The development comes in the wake of a securities class action styled Dolgicera v. Sarepta Therapeutics, Inc. et al., No. 1:25-cv-05317 (S.D.N.Y.), which seeks to represen ...

Core Viewpoint - KBR, Inc. experienced a significant decline in share price following the cancellation of a $20 billion contract with the U.S. Department of Defense's TRANSCOM, raising concerns about the company's previous positive statements regarding the contract's status [1][3][4]. Group 1: Contract Details - KBR's HomeSafe Alliance joint venture was awarded a contract in November 2021 to manage household goods for U.S. Armed Services and DoD civilians, valued at up to $20 billion over nine years [4]. - The contract aimed to centralize and improve the relocation process for military families, representing a major partnership with TRANSCOM [4]. Group 2: Company Communications - KBR's leadership expressed confidence in the contract's status, describing the partnership as "strong" and "excellent" during a May 2025 investor call, asserting a commitment to the program's success [5]. - Despite these assurances, operational issues were reportedly mounting behind the scenes, contradicting the company's public optimism [5][8]. Group 3: Contract Termination - On June 19, 2025, TRANSCOM terminated the HomeSafe contract due to failures in fulfilling obligations, including chronic delays and complaints about damaged goods [6]. - The termination shocked investors, especially given KBR's recent positive communications about the contract [7]. Group 4: Investigation and Legal Implications - Following the contract cancellation, Hagens Berman initiated an investigation into whether KBR misled investors regarding the contract's status [2][9]. - The firm is encouraging affected investors to report their losses and is seeking information from individuals with knowledge of the situation [2][9].

Core Viewpoint - The share price of CTO Realty Growth, Inc. significantly declined following allegations from Wolfpack Research regarding misleading statements about dividend sustainability and questionable financial practices [1][4]. Group 1: Allegations and Investigations - Wolfpack Research published a report accusing CTO of misleading investors about its dividend sustainability and engaging in dubious financial activities, leading to a decline in share price [1][4]. - Hagens Berman, a national shareholders rights firm, has initiated an investigation into CTO's practices and potential violations of securities laws, urging affected investors to come forward [2][3]. - The investigation focuses on CTO's adherence to accounting rules and the use of non-GAAP accounting metrics, particularly concerning the quality of its real estate portfolio and reported asset values [3][5]. Group 2: Financial Practices and Management - Wolfpack's report claims that CTO's management has misrepresented the quality of its properties, highlighting that some are in extreme financial distress and that the company relies on dilution to cover a $38 million dividend shortfall [4][5]. - The report criticizes CTO's definition of Adjusted Funds From Operation (AFFO), stating it excludes recurring capital expenditures, which is not consistent with industry peers, and suggests that management has inflated performance bonuses by $8 million [5][8]. - Allegations include misleading investors about dividend sustainability while enriching management and engaging in questionable accounting practices, such as using a sham loan to mask a tenant's failure [8].

Company Overview - Barnes & Noble Education, Inc. operates and manages campus bookstores, e-commerce sites, and digital courseware platforms for colleges, universities, and K–12 institutions across the United States [3] Allegations and Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Barnes & Noble, stemming from allegations of providing potentially misleading business information to the investing public [1] - On July 18, 2025, Barnes & Noble announced a delay in filing its annual report for the fiscal year ended May 3, 2025, due to an ongoing internal investigation into its digital sales recording methods [4] - Initial findings from the investigation suggest that Barnes & Noble may have overstated its accounts receivable by up to $23 million and expects to disclose material weaknesses in its internal controls [4] Market Reaction - Following the announcement of the investigation and the delay in filing, Barnes & Noble's stock price fell by $2.36 per share, or 21.02%, closing at $8.87 per share on July 21, 2025 [5]

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

NEWTOWN, Pa., July 23, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Encompass Health Corporation ("Encompass") (NYSE: EHC), resulting from allegations of providing potentially misleading information to the investing public.If you are an Encompass investor who suffered a substantial loss and would like to learn more, you can provide your contact information and trading details HERE.You can also contact attorney Eric Lechtzin of Edels ...

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ:REPL). The investigation concerns whether Replimune and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On July 22, 2025, Replimune disclosed that it received a Complete Response Letter (CRL) from the U.S. Food and Dru ...

ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) complied with federal securities laws. On July 22, 2025, Telix disclosed that the Company “received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Following th ...